Investing Advice Straight to Your Phone With TipRanks
TipRanks uses Natural Language Processing to give investing advice to roughly five million investors. Now, the company is out with a mobile app to bring the advice directly to users phones.
Uri Gruenbaum is the CEO and Co-founder of TipRanks. Gruenbaum explains that the reception to the new app has been very positive overall. The success has made him wish they built out this new app even sooner.
Gruenbaum explains that the overall goal is to help investors better understand the market and various options on the market. With NLP, TipRanks can analyze all of the information online and what analysts are saying, and then distill the best information and advice.
YouTube will offer creators a way to rejoin the streaming platform if they were banned for violating COVID-19 and election misinformation policies that are no longer in effect.
Lukas Alpert of MarketWatch explores how networks, brands, and ad buyers absorb the shockwaves when late‑night show hosts are suddenly cut — and brought back.
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.